Gara Jalqabaatti › Kansarii Ovarii › Massachusetts › Boston
Qorannoo klinikaalii Kansarii Ovarii Boston, MA keessatti
Qorannoo 61 Kansarii Ovarii f Boston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Boston
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Namoota walitti qabaa jiraSadarkaa 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Boston
A Study of PHST001 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Namoota walitti qabaa jiraSadarkaa 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Namoota walitti qabaa jira
- Dana-Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Namoota walitti qabaa jira
- Dana Farber Cancer Institute, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Boston
- Research Site, Boston
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Site 0221 - Tufts Medical Center - PPDS, Boston
- Site 0104 - Dana Farber Cancer Institute, Boston
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana Farber Cancer Institute, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Tufts Medical Center, Boston
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Namoota walitti qabaa jiraSadarkaa 2
- Massachusetts General Hospital, Boston
A Study of Isoquercetin in People With Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Beth Israel Deaconess Medical Center (Data Collection Only), Boston
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Massachusetts General Hospital, Boston
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Namoota walitti qabaa jiraSadarkaa 1/2
- Tufts, Boston
- Dana-Farber Cancer Institute, Boston
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Namoota walitti qabaa jiraSadarkaa 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Boston
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Namoota walitti qabaa jira
- Beth Israel Deaconess Medical Center, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Namoota walitti qabaa jiraSadarkaa 2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
Namoota walitti qabaa jiraSadarkaa 1
- Beth Israel Deaconess Medical Center, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- fi 2 dabalataa
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Namoota walitti qabaa jiraSadarkaa 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Namoota walitti qabaa jiraSadarkaa 2
- GSK Investigational Site, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
Namoota walitti qabaa jira
- Dana-Farber Cancer Institute, Boston
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Video Education With Result Dependent dIsclosure
Namoota walitti qabaa jira
- Dana Farber Cancer Institute, Boston
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Namoota walitti qabaa jira
- Massachusetts General Hospital-Cancer Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Site 0104, Boston
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Namoota walitti qabaa jira
- Dana Farber Cancer Institute, Boston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana-Farber Cancer Institute, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Namoota walitti qabaa jira
- Dana Farber Cancer Institute, Boston
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Namoota walitti qabaa jiraSadarkaa 2
- Massachusetts General Hospital, Boston
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Namoota walitti qabaa jiraSadarkaa 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana Farber Cancer Institute, Boston
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Dana Farber Cancer Institute, Boston
Qorannoo Kansarii Ovarii magaalota biroo keessatti
- Houston, TXQorannoo 89
- New York City, NYQorannoo 69
- Los Angeles, CAQorannoo 50
- Nashville, TNQorannoo 49
- Arlington, VAQorannoo 46
- Philadelphia, PAQorannoo 44
- Columbus, OHQorannoo 39
- St. Louis, MOQorannoo 38
- Chicago, ILQorannoo 36
- San Antonio, TXQorannoo 31
- Cleveland, OHQorannoo 30
- Pittsburgh, PAQorannoo 30
Qorannoo biroo Boston keessatti
- Saree OljooQorannoo 112
- Kansara Qara'a Non-Small CellQorannoo 90
- Saree (Gosoota Hunda)Qorannoo 85
- Kansara MetastatikiiQorannoo 63
- Kansarii ColorectalQorannoo 63
- Dhibee QaraQorannoo 62
- Kansarii ProstateQorannoo 59
- DepreshiniiQorannoo 52
- Kansa EndometiriyaaliiQorannoo 50
- Cufama OnneeQorannoo 44
- Leukemia Myeloidii HamaaQorannoo 44
- Kansarii PancreasQorannoo 43
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.